ADC Therapeutics appointments new CCO and CLO

Switzerland-headquartered antibody-drug conjugate specialist ADC Therapeutics (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17, 2022, and Peter Graham as chief legal officer, effective today.

Ms Harrington-Smith will join ADC Therapeutics from ImmunoGen (Nasdaq: IMGN), where she has served as senior vice president and CCO. Prior to ImmunoGen, she served as US commercial head of hematology at Swiss pharma giant Novartis (NOVN: VX), where she led the teams responsible for a broad portfolio of therapies in both benign and malignant hematologic diseases, including leading the commercial launch of Kymriah (tisagenlecleucel), and supporting the launch of Gilenya fingolimod).

“We are delighted to welcome Kristen to ADC Therapeutics. She has an extraordinary commercial background in the DLBCL landscape having led the commercial teams for serious hematological diseases, including major launches of innovative cell therapy products. We have complete conviction that Kristen is the right leader to maximize the potential of Zynlonta loncastuximab tesirine-lpyl) and take our commercial organization to the next level,” said Ameet Mallik, chief executive of ADC Therapeutics.